Ashton Thomas Securities LLC Makes New $5 Million Investment in Eli Lilly and Company $LLY

Key Points

• Ashton Thomas Securities LLC initiated a roughly $5 million position in Eli Lilly during the third quarter, purchasing 4,324 shares. Institutional investors collectively own 82.53% of the company.
• Eli Lilly reported strong quarterly results, with revenue up 38.6% year over year to $24.4 billion and EPS of $7.48, exceeding analyst expectations. Mounjaro and Zepbound sales rose sharply, reinforcing demand for the company’s diabetes and obesity treatments.
• Wall Street remains broadly positive, with an average “Moderate Buy” rating and a $1,320.25 price target, although insider selling, pricing pressure and one-time charges remain potential risks.

Ashton Thomas Securities LLC purchased a new position in Eli Lilly and Company (NYSE:LLY - Free Report) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 4,324 shares of the company's stock, valued at approximately $5,003,000.

A number of other institutional investors have also made changes to their positions in LLY. Marshall & Sterling Wealth Advisors Inc. grew its position in shares of Eli Lilly and Company by 60.0% during the 1st quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company's stock worth $37,000 after buying an additional 15 shares during the period. AlphaCentric Advisors LLC acquired a new stake in shares of Eli Lilly and Company in the 1st quarter valued at approximately $42,000. Caitlin John LLC acquired a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at approximately $64,000. IMG Wealth Management Inc. raised its holdings in Eli Lilly and Company by 500.0% in the second quarter. IMG Wealth Management Inc. now owns 60 shares of the company's stock worth $72,000 after purchasing an additional 50 shares during the period. Finally, Stonehage Fleming Financial Services Holdings Ltd acquired a new stake in Eli Lilly and Company in the second quarter worth $88,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Eli Lilly and Company

In related news, EVP Patrik Jonsson sold 6,500 shares of the company's stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the transaction, the executive vice president directly owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the transaction, the executive vice president directly owned 11,875 shares of the company's stock, valued at approximately $14,131,250. The trade was a 29.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 13,500 shares of company stock valued at $15,958,170. 0.14% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on LLY. Sanford C. Bernstein reissued an "outperform" rating and issued a $1,450.00 price target on shares of Eli Lilly and Company in a report on Monday. Weiss Ratings raised Eli Lilly and Company from a "buy (b)" rating to a "buy (b+)" rating in a research note on Thursday, October 15th. Truist Financial raised their price objective on Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the stock a "buy" rating in a research note on Friday, August 7th. Wall Street Zen lowered Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Saturday, October 17th. Finally, The Goldman Sachs Group reaffirmed a "buy" rating and issued a $1,413.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, October 20th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $1,320.25.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $1,372.01 on Friday. The stock has a 50 day moving average price of $1,194.34 and a 200 day moving average price of $1,090.89. Eli Lilly and Company has a 52 week low of $812.25 and a 52 week high of $1,408.38. The stock has a market capitalization of $1.29 trillion, a PE ratio of 46.04, a price-to-earnings-growth ratio of 1.73 and a beta of 0.46. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating analysts' consensus estimates of $5.68 by $1.80. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The firm had revenue of $24.40 billion for the quarter, compared to analyst estimates of $22.58 billion. During the same period in the prior year, the firm posted $7.02 EPS. The company's revenue for the quarter was up 38.6% on a year-over-year basis. Analysts predict that Eli Lilly and Company will post 33.22 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 annualized dividend and a yield of 0.5%. Eli Lilly and Company's payout ratio is presently 23.22%.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong earnings and sales beat estimates. Third-quarter revenue rose 39% year over year to $24.4 billion, while adjusted EPS was $7.48 versus the roughly $5.68 analyst consensus. Reported EPS was $7.22, up from $6.21 a year earlier. Eli Lilly earnings report
• Positive Sentiment: Demand for GLP-1 drugs continues to accelerate. Mounjaro sales increased 65% to $10.7 billion, while Zepbound revenue climbed 49% to $5.35 billion. The performance reinforced expectations that Lilly can continue gaining share in the rapidly expanding diabetes and obesity markets. Eli Lilly stock jumps on Mounjaro and Zepbound earnings
• Positive Sentiment: Management sharply increased its outlook. Lilly raised 2026 revenue guidance to $91 billion-$92 billion from $85 billion-$87 billion, lifting the midpoint by $5.5 billion. The company also highlighted regulatory progress, including Mounjaro’s cardiovascular-risk indication and approval of once-weekly insulin Onswik. Eli Lilly raises revenue outlook
• Positive Sentiment: Pipeline momentum added to investor enthusiasm. Phase 3 data showed experimental retatrutide produced greater A1C reductions and more than double the weight loss of Ozempic 2 mg in adults with type 2 diabetes, strengthening Lilly’s competitive position against Novo Nordisk. Retatrutide trial results
• Neutral Sentiment: Investors should monitor the quality and durability of growth. Realized prices declined about 15%, although a 53% volume increase more than offset the pressure. Approximately $900 million of quarterly benefits came from Jardiance milestones and rebate adjustments, neither of which is expected to recur fully.
• Negative Sentiment: One-time deal-related charges and access concerns remain risks. Lilly recorded about $4.2 billion in acquired in-process R&D charges, while reports also noted a Foundayo sales miss and potential employer concerns about covering costly weight-loss drugs. These factors could pressure margins or slow future demand. Eli Lilly pricing and earnings reaction

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.